Randomized Trial to Evaluate Cardiometabolic and Endothelial Function in Patients with Plasma HIV-1 RNA Suppression Switching to Darunavir/Ritonavir with or without Nucleoside Analogues

REFERENCES

• Hammer S, Eron J, Reiss P, et al. Antiretroviral treatment of adult HIV infection. 2008 recommendations of the Inter-national AIDS Society-USA Panel. JAMA. 2008;300(5): 555–570
   PubMed Web of Science ®Google Scholar
• US Department for Health and Social Security. Guidelines for the use of antiretroviral agents in HIV-1 infected adults and adolescents, January 10,2011. http://www.aidsinfo.nih.gov/Guidelines/GuidelineDetail.aspx?GuidelinelD=7. Accessed March 2011.
   Google Scholar
• European AIDS Clinical Society (EACS). Guidelines for the clinical management of HIV infected adults in Europe. http://www.europeanaidsclinicalsociety.org/guideline-spdf/1_Treatment_of_HIV_Infected_Adults.pdf. Accessed September 2010.
   Google Scholar
• Arribas J, Horban A, Gerstoft J, et al. The MONET trial: Darunavir/ritonavir with or without nucleoside analogues, for patients with HIV RNA below 50 copies/ml. AIDS. 2010;24(2):223–230.
   PubMed Web of Science ®Google Scholar
• Clumeck N, Rieger A, Banhegyi D, et al. 96 week results from the MONET trial: A randomized comparison of darunavir/ritonavir with versus without nucleoside ana-logues, for patients with HIV RNA<50 copies/mL at base-line [published online ahead of print June 2011]. J Antimi- crob Chemother
   Google Scholar
• Katlama C, Valentin MA, Algarte-Genin M, et al. Efficacy of darunavir/ritonavir as single-drug maintenance therapy in patients with HIV-1 viral suppression: A randomized open-label non-inferiority trial, MONOI-ANRS 136. AIDS. 2010;24(15):2365–2374.
   PubMed Web of Science ®Google Scholar
• Valentin M, Flandre P, Kolta S, et al. Fat tissue distribu-tion changes in HIV-infected patients with viral suppres-sion treated with darunavir-ritonavir monotherapy versus 2NRTI5 + DRV/r in the MONOI-ANRS 136 randomised trial: Results at 48 weeks [abstract 0-262]. Presented at: Conference on Retroviruses and Opportunistic Infections (CR01); February 2010; San Francisco, USA.
   Google Scholar
• Randell P, Jackson A, Zhong L, Yale K, Moyle G. The impact of tenofovir on insulin sensitivity and lipids in healthy volunteers [abstract H-2307]. Presented at: 48th Annual ICAAC/IDSA Meeting; October 2008; Washington, DC, USA.
   Google Scholar
• Grunfeld C, Kotler D, Arnett D, et al. Contribution of meta-bolic and anthropometric abnormalities to cardiovascular disease risk factors. Circulation. 2008;118:1–9.
   Google Scholar
• Guaraldi G, Stentarelli C, Zona S, et al. Lipodystrophy and anti-retroviral therapy as predictors of sub-clinical atherosclerosis in human immunodeficiency virus infected subjects. Atherosclerosis. 2010;208:222–227.
   PubMed Web of Science ®Google Scholar
• Law M, Friis-Moller N, El-Sadr W, et al. The use of the Framingham equation to predict myocardial infarctions in HIV-infected patients: Comparison with observed events in the D:A:D study. HIV Med. 2006;7:218–230.
   PubMed Web of Science ®Google Scholar
• Deanfield J, Halcox J, Rabelink T. Endothelial function and dysfunction: Testing and clinical relevance. Circulation. 2007;115:1285–1295.
   PubMed Web of Science ®Google Scholar
• Yeboah J, Crouse J, Hsu F, Burke G, Herrington D. Brachial flow-mediated dilation predicts incident cardiovascular events in older adults: The Cardiovascular Health Study. Circulation. 2001104: 257–262.
   Google Scholar
• Boos C, Lip G, Blann A. Circulating endothelial cells in cardiovascular disease. J Am Coll Cardiol. 2006;48: 1538–1547.
   PubMed Web of Science ®Google Scholar
• Solages A, Vita J, Thornton D, et al. Endothelial function in HIV-infected persons. Clin Infect Dis. 2006;42:1325–1332.
   PubMed Web of Science ®Google Scholar
• Torriani F, Komarow L, Parker R, et al. Endothelial func-tion in human immunodeficiency virus-infected antiret-roviral-naive subjects before and after starting potent antiretroviral therapy. The ACTG 5142s. J Am Coll Cardiol. 2008;52:569–576.
   PubMed Web of Science ®Google Scholar
• Murphy R, Berzins B, Zala C, et al. Change to atazanavir/ritonavir treatment improves lipids but not endothelial function in patients on stable antiretroviral therapy. AIDS. 2010;24:885–890.
   PubMed Web of Science ®Google Scholar
• Corretti MC, Anderson TJ, Benjamin EJ, et al. Guidelines for the ultrasound assessment of endothelial dependent flow-mediated vasodilation of the brachial artery: A report of the International Brachial Artery Reactivity Task Force. J Am Coll Cardiol. 2002;39:257–265.
   PubMed Web of Science ®Google Scholar
• Bertolini F, Shaked Y, Mancuso P, Kerbel RS. The multifaceted circulating endothelial cell in cancer: Towards marker and target identification. Nature Rev Cancer 2006;6:835–845.
   PubMed Web of Science ®Google Scholar
• Barbieri D, Abbracchio MP, Salvioli S, et al. Apoptosis by 2-chloro-2’-deoxy-adenosine and 2-chloro-adenosine in human peripheral blood mononuclear cells. Neurochem Int. 1998;32:493–504.
   PubMed Web of Science ®Google Scholar
• Nemes E, Lugli E, Bertoncelli L, et al. CD4+ T cell differ-entiation, Treg and gag-specific T lymphocytes are unaf-fected by CD4-guided treatment interruption and therapy resumption. AIDS. 2011;25:1443–1453.
   PubMed Web of Science ®Google Scholar
• Flammer A, Vo N, Hermann F, et al. Effect of atazanavir versus other protease inhibitor-containing antiretroviral therapy on endothelial function in HIV-infected persons: A randomized controlled trial. Heart. 2009;95:385–390.
   PubMed Web of Science ®Google Scholar
• Hunt P, Sinclair E, Epling I, et al. Impaired endothelial func-tion is associated with increased frequencies of CCR5+ and HIV-specific T cells during treated HIV infection [abstract 160]. Presented at: 18th Conference on Retrovi-ruses and Opportunistic Infections (CR01); February 2011; Boston, MA, USA.
   Google Scholar
• Bots M, Westerink J, Rabelink T, de Koning E. Assessment of flow-mediated vasodilation (FMD) of the brachial artery: Effects of technical aspects of the FMD measurement on the FMD response. Eur Heart J. 2005;26:363–368.
   PubMed Web of Science ®Google Scholar
• Hsue P, Hunt P, Wu Y, et al. Association of abacavir and impaired endothelial function in treated and suppressed HIV-infected patients. AIDS. 2009;23(15):2021–2027.
   PubMed Web of Science ®Google Scholar
• Dube M, Shen C, Mather K, Waltz J, Greenwald M, Gupta S. Relationship of body composition, metabolic status, antiretroviral use, and HIV disease factors to endothelial dysfunction in HIV-infected subjects. AIDS Res Hum Ret-roviruses. 2010;26 (8):847–854.
   PubMed Web of Science ®Google Scholar
• López M, Vispo E, Román JS, et al. High risk of endothelial dysfunction in HIV individuals may result from deregulation of circulating endothelial cells and endothelial progenitor cells [published online ahead of print September 21,20111. AIDS Res Hum Retro viruses.
   Google Scholar
• Hill A, Sawyer A, Gazzard B. Effects of first-line use of nucle-oside analogues, efavirenz, and ritonavir-boosted protease inhibitors on lipid levels. HIV Clin Trials. 2009;10(1):1–12.
   PubMed Web of Science ®Google Scholar
• Pozniak A, Suleiman J, Lu B, et al. Reduction in cholesterol and triglycerides after tenofovir DF (TDF) addition/switch in HIV-infected treatment experienced patients participating in three controlled trials [abstract 159]. Presented at: 7th International Congress on Drug Therapy in HIV Infection; November 2004; Glasgow, UK.
   Google Scholar
• Cooper RD, Wiebe N, Smith N, et al. Systematic review and meta-analysis: Renal safety of tenofovir diso-proxil fumarate in HIV-infected patients. Clin Infect Dis. 2010;51(5):496–505.
   PubMed Web of Science ®Google Scholar
• Justice A, McGinnis K, Skanderson M, et al. Towards a combined prognostic index for survival in HIV infec-tion: The role of non-HIV biomarkers. HIV Med. 2010;11: 143–151.
   PubMed Web of Science ®Google Scholar
• Ibrahim F, Hamzah L, Jones R, et al. Baseline renal func-tion as predictor of mortality and renal disease progression in HIV-infected patients [abstract 165]. Presented at: 18th Conference on Retroviruses and Opportunistic Infections (CR01); February 2011; Boston, MA, USA.
   Google Scholar